Lupus & antiphospholipid syndrome

Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus

J RheumatolPublished Prospective cohort study

Main finding · LLDAS attainment (patients not in LLDAS at enrolment)Result — go to the resultHazard ratio 1.37 95% CI 1.16–1.61

Authors' conclusion

LLDAS attainment is protective from flare in recent onset SLE. Significant protection from damage accrual was not observed because of low rates of damage accrual in the first years after SLE diagnosis.

Study context

Population
Patients with systemic lupus erythematosus (SLE) in a 13-country longitudinal cohort, 2013–2020
Participants
4,106 patients
Exposure
Inception cohort vs noninception cohort
  • Inceptionn = 680
Outcome
Association of LLDAS attainment with damage accrual and flare
Methodological detailsmultinational (13-country) longitudinal cohort, inception vs noninception cohort comparison, survival analyses
  • Multinational (13-country) longitudinal cohort
  • Inception vs noninception cohort comparison
  • Survival analyses

Main finding

As reported in the abstract

LLDAS attainment (patients not in LLDAS at enrolment)

Hazard ratio

1.37

95% CI 1.16–1.61

P < 0.001

Inceptionvs Noninception
HR 1.37 (95% CI 1.16–1.61); P < 0.001

Observational data: associations, not effects.

Further findings

In LLDAS at enrolment

P < 0.001

Organ damage accrual in inception cohort · median 2.2 years of follow-up
13.6% · 88

In Lupus Low Disease Activity State (LLDAS) at enrolment

Three-quarters of both groups achieved LLDAS at least once during follow-up

Original publication

Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus. J Rheumatol. Published 15 March 2024. doi:10.3899/jrheum.2023-0900

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.